Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rupatadine for chronic idiopathic urticaria: 6-week randomized double-blind placebo-controlled phase III trial
2004-000771-34Phase 3Active
- Sponsor
- Uriach
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rupatadine in chronic idiopathic urticaria (CIU) (3 arms), sponsored by Uriach. Primary endpoints: Primary CIU symptom severity endpoint over 4 weeks and Primary CIU symptom severity endpoint over 6 weeks. Started Sep 2004; status: active.
02
Drugs
rupatadine
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2004-000771-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000771-34.